Early Docetaxel for prostate cancer improves survival

Early treatment with Docetaxel chemotherapy improves survival for patients with incurable prostate cancer.

Two studies have now confirmed this benefit – CHARRTED and STAMPEDE. Chemotherapy was previously held in reserve for patients who were not responding well to conventional hormonal therapy. “This is a paradigm shift in the management of patients with advanced prostate cancer”, said Dr Jamie Mills of The Nottingham Oncology Group. Both studies show a survival advantage and that they require fewer additional treatments in the future. “Starting chemotherapy early for patients when they have been diagnosed with prostate cancer which has spread outside of the prostate gland produces a more rapid and prolonged improvement in their disease than we have seen previously with hormonal therapy alone” says Dr Daniel Saunders, Consultant Oncologist. He goes on to say “people are more likely to tolerate chemotherapy well if we treat them earlier rather than wait until their cancer is progressing”

Docetaxel chemotherapy is routinely available for patients treated for prostate cancer at The Nottingham Oncology Group. Other treatments such as radiotherapy, Abiraterone, Enzalutamide and Radium-223 are all available – your expert clinical oncologist will tailor your treatment to your indvidual needs.

Latest News

  • October 3, 2015
    Early Docetaxel for prostate cancer improves survival

    Early treatment with Docetaxel chemotherapy imp...

    Read More
  • July 30, 2015
    Prostate Cancer Genetic Signatures

    A better understanding of the genetics of prost...

    Read More
  • May 13, 2015
    Where are the voices for radiotherapy?

    It is not well publicised – but the main ...

    Read More